Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Jpn J Infect Dis ; 75(2): 202-204, 2022 Mar 24.
Article in English | MEDLINE | ID: covidwho-1761197

ABSTRACT

Many studies have been conducted on ventilator-associated complications (VACs) in patients with coronavirus 2019 (COVID-19). However, in these studies, the causative organisms were similar, and there were no reports on VAC corresponding with Corynebacteria. Coryneforms are frequently cultured in cases of polymicrobial infections and are usually considered contaminants in respiratory specimens. However, Corynebacterium pseudodiphtheriticum or C. striatum is known to be a pathogen in lower respiratory tract infections. We report three cases of VAC, probably due to C. pseudodiphtheriticum, in patients with COVID-19. If purulent lower respiratory tract specimens showed coryneform predominantly upon Gram staining, empirical therapy should be started. Furthermore, species identification and drug susceptibility testing should be performed.


Subject(s)
COVID-19 , Coinfection , Corynebacterium Infections , Mycobacterium tuberculosis , Coinfection/complications , Corynebacterium , Corynebacterium Infections/complications , Corynebacterium Infections/diagnosis , Humans , Microbial Sensitivity Tests , Respiration, Artificial/adverse effects
2.
A A Pract ; 14(9): e01287, 2020 Jul.
Article in English | MEDLINE | ID: covidwho-992616

ABSTRACT

Methemoglobinemia is a rare disorder of the blood in which there is an increase in methemoglobin, which occurs when hemoglobin is present in the oxidized form. Methemoglobin impairs hemoglobin's ability to transport oxygen, produces functional anemia, and leads to tissue hypoxia. We report the successful management of a case of refractory hypoxia due to acutely acquired methemoglobinemia in a patient undergoing treatment for coronavirus disease 2019 (COVID-19) pneumonia. The cause of methemoglobinemia in this patient remains unknown. Hypoxia and methemoglobinemia did not respond to methylene blue and required administration of packed red blood cell transfusions.


Subject(s)
Coronavirus Infections/complications , Hypoxia/etiology , Methemoglobinemia/complications , Pneumonia, Viral/complications , Respiratory Insufficiency/etiology , Acute Kidney Injury/complications , Acute Kidney Injury/therapy , Aged , Antibodies, Monoclonal, Humanized/therapeutic use , Antioxidants/therapeutic use , Ascorbic Acid/therapeutic use , Betacoronavirus , COVID-19 , Coronavirus Infections/drug therapy , Corynebacterium , Corynebacterium Infections/complications , Corynebacterium Infections/therapy , Cytokine Release Syndrome/complications , Enzyme Inhibitors/therapeutic use , Erythrocyte Transfusion , Hematinics/therapeutic use , Humans , Hydroxocobalamin/therapeutic use , Hydroxychloroquine/therapeutic use , Hypoxia/therapy , Male , Methemoglobinemia/therapy , Methylene Blue/therapeutic use , Pandemics , Pneumonia, Bacterial/complications , Pneumonia, Bacterial/therapy , Pneumonia, Viral/drug therapy , Renal Replacement Therapy , Respiratory Insufficiency/therapy , SARS-CoV-2 , Shock, Septic/complications
SELECTION OF CITATIONS
SEARCH DETAIL